ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0042 • ACR Convergence 2025

    Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis

    Steven Dang1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, liqun Diao5, Igor Jurisica6, Vinod Chandran7 and Lihi Eder8, 1Institute of Medical Science, University of Toronto, Toronto, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, 3Women’s College Research Institute, Toronto, Canada, 4Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, 5Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, 6University Health Network, Toronto, Canada, 7Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 8University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
  • Abstract Number: 0019 • ACR Convergence 2025

    Single cell characterization of the circulating immune system in Sjögren’s Syndrome

    Alejandro Gómez Gómez1, Héctor Corominas2, Rosario Garcia Vicuña3, Mercedes Freire González4, Sheila Melchor-Díaz5, Paloma Vela Casasempere6, Paula Estrada-Alarcón7, Jose Luis Tandaipan8, Monica Fernandez Castro9, Sara Maria Rojas Herrera10, Marina Rodríguez López11, Beatriz Paredes-Romero12, Santiago Muñoz13, Marta López14, Ignacio Braña15, Gema Bonilla16, Raúl Menor Almagro17, Sara Manrique-Arija18, Mª Angeles Blazquez Cañamero19, Lilian López-Núñez20, Carles Galisteo Veiga21, Juan José Alegre-Sancho22, Jose Rosas Gómez de Salazar23, Jose Javier Pérez Venegas24, Judit Font-Urgelles25, José Andrés Román Ivorra26, José Miguel Sequí-Sabater27, Rafaela Ortega-Castro28, Clara Moriano29, Guadalupe Manzano-Canabal30, Cilia Peralta-Ginés31, Javier Narváez32, Rafael Cáliz-Cáliz33, Javier Martínez-Ferrin34, Lara Sánchez Bilbao35, Belén Serrano-Benavente36, Natalia Boix- Martí37, Ares Selles-Rius38, Maribel Pérez39, Juan Cañete40, Núria Palau Balaña38, Damiana Alvarez Errico39, Yolanda Guillén41, Juan Ángel Patiño Galindo41, Antonio Julià1, Sara Marsal Barril42 and Jose Luis Andreu43, 1Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, 2Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Barcelona, Spain, 3Hospital Universitario de la Princesa, Madrid, Spain, 44 Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, 5Hospital Universitario 12 de Octubre, Rheumatology, Madrid, Madrid, 6Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 7Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 8Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, 9PUERTA DE HIERRO HOSPITAL, Madrid, Spain, 10Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, 11Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, 12Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, 13Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, 14Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 15Hospital Universitario Central de Asturias, Oviedo, Spain, 16Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, 17Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, 18Hospital Regional Universitario Málaga, Malaga, Spain, 19Hospital Ramon y Cajal, Madrid, Spain, 20Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, 21Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, 22Hospital Universitario Doctor Peset, Valencia, Spain, 23Hospital Marina Baixa, PALMA DE MALLORCA, Spain, 24Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, 25Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 26Hospital Universitari i Politècnic La Fe, Valencia, Spain, 27Hospital Universitario La Fe (Valencia), Valencia, Spain, 28Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 29Hospital León, LEON, Castilla y Leon, Spain, 30Hospital Virgen de la Concha (Zamora), Zamora, Spain, 31Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 32Hospital Universitario de Bellvitge, Barcelona, Spain, 33Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, 34Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, 35Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 36Hospital Gregorio Marañon, Madrid, Spain, 37Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, 38Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, 39IMIDomics, Barcelona, Barcelona, Spain, 40Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 41IMIDomics, Barcelona, Spain, 42Vall Hebron Hospital Research Institute, Barcelona, Spain, 43Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…
  • Abstract Number: 0088 • ACR Convergence 2025

    Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis

    Lyndsey Cole1, Brendan Allen2, Sucai Liu2, Marie Feser3, Le Yi Phyo2, LauraKay Moss2, Daniel Frank2, J. Kirk Harris2, Kristen Demoruelle4, Kevin Deane5, V. Michael Holers6 and Kristine Kuhn7, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 6University of Colorado Anschutz Medical Campus, Aurora, 72022 - 2023 / Adult/ University of Colorado, Aurora, CO

    Background/Purpose: The mucosal origins hypothesis of RA proposes that immune responses to microorganisms at mucosal sites (e.g. intestine) lead to systemic inflammation and autoimmunity. Little…
  • Abstract Number: 0082 • ACR Convergence 2025

    IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model

    Hongling Tian, Lidan Liang, Chenjuan Zhu, Bin Li, Lei Cao, Meng Ni, Fan Chen, Zhimin Zhang, Min Wu, Tong Liu, Jinyang Li, Yao Xiong, Li Li, Shuaixiang Zhou, Enhong Zhong and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: Interleukin 1 receptor accessory protein (IL1RAP) serves as a co-receptor that forms receptor complexes with IL1R1, ST2, and IL36R and mediates signaling pathways triggered…
  • Abstract Number: 0039 • ACR Convergence 2025

    Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome

    randy Cron1, Abhishek Kamath1, Mingce Zhang1, Devin Abhser2, Lesley Jackson1 and Walter Winn Chatham3, 1University of Alabama at Birmingham, Birmingham, AL, 2Kaiser Permanente Research Bank, Oakland, CA, 3University of Nevada, Las Vegas, Las Vegas, NV

    Background/Purpose: Severe COVID-19 infection resulting in hospitalization shares features with frequently fatal cytokine storm syndromes (CSS), such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome…
  • Abstract Number: 0001 • ACR Convergence 2025

    ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

    Gang Bian1, Tengteng Li1, Huiling Liu2, Zaoshun Hu2, Peng Chen1, Jay Mei3 and Bing Hou3, 1Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), 2Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), 3Antengene Corporation, Shanghai, China (People's Republic)

    Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
  • Abstract Number: 0005 • ACR Convergence 2025

    LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells

    Fengxia Li1, Jianming Sun1, Hailin Wang1, Yan Zhu1, Xiaoxiao Liu1, Jing Li1, Yurong Qin1, Guojin Wu1, Jing Guan1, Min Chen1, Jordan Zhu2, Xiaoqiang Kang1, Xiao Huang1 and Hong Ling1, 1Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), 2Nanjing Leads Biolabs Co., Ltd., Nan Jing

    Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
  • Abstract Number: 0036 • ACR Convergence 2025

    Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus

    Mehmet Hocaoglu1 and Amr Sawalha2, 1University of Pittsburgh Medical Center, Piitsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
  • Abstract Number: 0034 • ACR Convergence 2025

    Meta-Analysis of GWAS data from 10,003 Sjögren’s Disease Cases Identifies Thirteen Sjögren’s Risk Loci.

    Marcin Radziszewski1, Bhuwan Khatri1, Philip Stuart2, Astrid Rasmussen1, Kandice Tessneer1, Cherilyn Pritchett-Frazee1, Matthew Pattrick2, Elena Pontarini3, michele Bombardieri4, Maureen Rischmueller5, Marika Kvarnström6, Torsten Witte7, Hendrika Bootsma8, Gwenny Verstappen9, Frans Kroese9, Arjan Vissink10, Sarah Pringle9, Athanasios Tzioufas11, Clio Mavragani12, Alan Baer13, Marta Alarcon-Riquelme14, Javier Martin15, Xavier Mariette16, Gaetane Nocturne17, Jacques-Olivier Pers18, Jacques-eric GOTTENBERG19, Wan-Fai Ng20, Caroline Shiboski21, Kimberly Taylor22, Lindsey Criswell23, Blake M. Warner24, A. Darise Farris1, Judith James1, R Hal Scofield1, Joel Guthridge1, Daniel Wallace25, Swamy Venuturupalli26, Mike Brennan27, Juliana Imgenberg-Kreuz28, Lars Rönnblom28, Eva Baecklund29, Maija-Leena Eloranta28, Svein Joar Augländ Johnsen30, Roald Omdal31, Lara Aqrawi32, Øyvind Palm33, Johan Brun34, Daniel Hammenfors34, Malin Jonsson34 and Silke Appel34, Sara Bucher35, Helena Forsblad36, Thomas Mandl37, Per Eriksson38, Marie Wahren-Herlenius6, Erik Abner39, Tõnu Esko39, Benjamin A. Fisher40, Rachel Gordon41, Gabriela Hernandez-Molina42, Adrian Lee43, Johann Gudjonsson44, Lam Tsoi44, Gunnel Nordmark29 and Christopher Lessard1,1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Michigan Medical School, Ann Arbor, MI, 3Queen Mary University of London, London, United Kingdom, 4Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, 5RheumatologySA, Adelaide, Australia, 6Karolinska Institutet, Stockholm, Sweden, 7Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, 8UMCG, Groningen, Netherlands, 9University Medical Center Groningen, Groningen, Netherlands, 10University of Groningen, Leek, Netherlands, 11LAIKO HOSPITAL, Athens, Greece, 12National and Kapodistrian University of Athens, Athens, Greece, 13Johns Hopkins University School of Medicine, Baltimore, MD, 14Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 15Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, 16Université Paris-Saclay, Le Kremlin Bicetre, France, 17University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, 18CHU de Brest, Brest, France, 19Hautepierre Hospital, STRASBOURG, Alsace, France, 20Newcastle University, Gateshead, United Kingdom, 21University of California San Francisco, San Francisco, CA, 22UC San Francisco, San Francisco, CA, 23NIH/NHGRI, Bethesda, MD, 24National Institutes of Health, Bethesda, MD, 25Cedars Sinai Medical Center, Studio City, CA, 26Attune Health, Beverly Hills, CA, 27Atrium Health, Charlotte, NC, 28Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 29Uppsala University, Uppsala, Sweden, 30Stavanger University Hospital, Stavanger, Norway, 31Stavanger University Hospital, Stavanger, Nepal, 32Kristiania University College, Oslo, Norway, 33Oslo University Hospital, Oslo, Norway, 34University of Bergen, Bergen, Norway, 35Örebro University, Örebro, Sweden, 36University of Gothenburg, Gothenburg, Sweden, 37Lund University, Malmö, Sweden, 38Linköping University, Linköping University, 39University of Tartu, Tartu, Estonia, 40 King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, 41University of Pittsburgh School of Medicine, Pittsburgh, PA, 42Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 43University of Sydney, Sydney, Australia, 44University of Michigan, Ann Arbor, MI.

    Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition with a complex genetic architecture. To date, 22 genome-wide significant (GWS) SjD risk loci have been…
  • Abstract Number: 0100 • ACR Convergence 2025

    Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors

    Beatriz Vellón-García1, Gema Dolores García-Delgado2, Adrián Llamas Urbano3, Yas Hanaee3, Pedro Ortiz Buitrago4, Christian Merlo5, Maria del carmen abalos-aguilera5, julio Manuel Martinez Moreno6, Iván Arias de la Rosa7, María Dolores López-Montilla8, Rafaela Ortega-Castro9, Jerusalén Calvo10, Lourdes Ladehesa11, Clementina López Medina12, María Ángeles Puche-Larrubia13, Nuria Barbarroja14, Eduardo Collantes estévez15, Alejandro Escudero-contreras5, Chary López pedrera16, Jose manuel Villalba17 and Carlos Pérez Sánchez18, 1Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, 2Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, 3Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, 4Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, 5Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, 6Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain, Cordoba, Spain, 7IMIBIC/FIBICO/Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Toledo, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Toledo, Spain., Córdoba, Spain, 8Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 10IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 11IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 12Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 13Reina Sofia University Hospital, Granada, Spain, 14Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 15Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 16Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 17Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, 18Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain

    Background/Purpose: This study aims to:Characterize the NAD+ metabolome in CIRDs and their association with clinical traits.Evaluate the impact of TNFi therapy on NAD+ metabolome alterations.Test…
  • Abstract Number: 0102 • ACR Convergence 2025

    Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling

    Dachun Zhuo1, Yulong Tang2, Xiaobei Ma2, Chengchun Geng1, Jiangnan Xie1, Jiucun Wang2 and Jing Liu1, 1Fudan University, Shanghai, Shanghai, China (People's Republic), 2Fudan university, Shanghai, China (People's Republic)

    Background/Purpose: Iron metabolism dysregulation has been increasingly recognized as a key factor in the pathogenesis of inflammatory arthritis, with evidence linking altered iron homeostasis to…
  • Abstract Number: 0092 • ACR Convergence 2025

    SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging

    Mojtaba S. Fazli1, Mariani Diaz Deluna2, Suzanne Tamang2 and Robert Fairchild2, 1Stanford University, San Francisco, CA, 2Stanford University, Stanford, CA

    Background/Purpose: Rheumatology musculoskeletal ultrasound (MSKUS) is a powerful technique to identify and differentiate arthritidies joint pathology, yet MSKUS is highly dependent on user experience. Techniques…
  • Abstract Number: 0081 • ACR Convergence 2025

    Trans-endothelial Trafficking of Fibroblast-like Synoviocytes Amplifies Synovial Inflammation in Rheumatoid Arthritis

    Jaeyeon Kim1, Sanaz Panahandeh2, Hieu Nguyen3, Kainat Mian4, Hadijat Makinde4, Kyoung Jae Won5, Arminja Kettenbach3, Harris R Perlman4, Costantino Pitzalis6 and Nunzio Bottini7, 1Cedars Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Northwestern University, Chicago, IL, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6QMUL, Bromley Kent, United Kingdom, 7Cedars Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: The discovery of circulating fibroblast-like synoviocyte (FLS), known as PRIME cells, in RA patients suggests that synovial FLS may enter the circulation through blood…
  • Abstract Number: 0068 • ACR Convergence 2025

    Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis

    Aryan Patel1, Osama Al Zoubi2 and Shiva Shahrara3, 1University of Illinois at Chicago, Chicago, 2University of Illinois at Chicago, Chicago, IL, 3University of Illinois, Chicago, IL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
  • Abstract Number: 0066 • ACR Convergence 2025

    RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.

    Yidan Wang1, Samuel Dowling2, Jessica Maciuch2, Vanessa Manada De Lobos2, Meghan Mayer2, Kainat Mian1, Tyler Therron3, Hadijat Makinde1, Carla Marie Cuda1, Deborah Rachelle Winter4 and Harris R Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern Feinberg School of Medicine, Chicago, IL, 4Northwestern University, Skokie, IL

    Background/Purpose: Tissue-resident monocyte-lineage cell (TRMC) are an extravascular population distinct from circulating monocytes and synovial macrophages and are critical for the development of inflammatory arthritis.…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology